However, pre-clinical work in mouse models of CRC indicates that blockade of IL-34-associated MCSF-1R pathway as monotherapy provides minimal therapeutic benefit despite such a treatment associates with marked reduction of the number of TAMs. This evidence concerns the gene IL34 and colorectal carcinoma.